|
市場調査レポート
商品コード
1688976
錐体杆体ジストロフィーの世界市場：タイプ別、治療タイプ別、エンドユーザー別、地域別の分析、規模、動向、COVID-19の影響、予測（～2030年）Global Cone Rod Dystrophy Market: Analysis By Type, By Treatment Type, By End User, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2030 |
||||||
|
|||||||
| 錐体杆体ジストロフィーの世界市場：タイプ別、治療タイプ別、エンドユーザー別、地域別の分析、規模、動向、COVID-19の影響、予測（～2030年） |
|
出版日: 2025年03月26日
発行: Daedal Research
ページ情報: 英文 99 Pages
納期: 即納可能
 |
- 全表示
- 概要
- 図表
- 目次
錐体杆体ジストロフィーは、網膜の錐体細胞に影響を及ぼす遺伝性の眼疾患群を表す用語です。これらの細胞は、網膜として知られる領域で眼球の後方に並んでいます。錐体細胞は網膜全体に存在しますが、中心部（黄斑部）に集中しています。これらは中心視（読書）に役立ちます。杆体視細胞は、ごく中心部を除く網膜全体に存在し、夜間視力に役立ちます。世界の錐体杆体ジストロフィーの市場規模は、2024年に1億3,129万米ドルであり、2030年までに1億7,759万米ドルに達すると予測されます。
世界の錐体杆体ジストロフィー市場の成長は、遺伝性疾患に対する意識の高まりや、効果的な治療に対する需要の増加といった要因によってもたらされます。また、糖尿病も錐体杆体ジストロフィー市場の成長に大きな影響を与えます。National Eye Instituteの近年の推計では、米国だけでも約4万人に1人が錐体杆体ジストロフィーに罹患しており、効果的な治療オプションの重要な必要性が浮き彫りになっています。現在のところ、錐体杆体ジストロフィー（CRD）患者の視力低下を食い止める治療法はありません。CRDの治療の第一の目標は、疾患の進行を遅らせ、残った視力を維持し、罹患者の生活の質を向上させることです。CRDの将来的な治療法としては、遺伝子治療、幹細胞治療、網膜移植などが考えられます。今後、錐体杆体ジストロフィー市場は、政府の啓発プログラムの増加、臨床試験の増加、遺伝子治療と網膜インプラントの進歩、個別化医療への注目の高まりなどにより、2025年～2030年に大幅に拡大すると予測されます。市場は、2025年～2030年の予測期間にCAGRで5.33%の成長が見込まれます。
当レポートでは、世界の錐体杆体ジストロフィー市場について調査分析し、市場力学、COVID-19の影響、競合情勢などの情報を提供しています。
目次
第1章 エグゼクティブサマリー
第2章 イントロダクション
- 錐体杆体ジストロフィー：概要
- 錐体杆体ジストロフィーのイントロダクション
- 錐体杆体ジストロフィーのセグメンテーション：概要
- 錐体杆体ジストロフィーのセグメンテーション
第3章 世界市場の分析
- 世界の錐体杆体ジストロフィー市場：分析
- 世界の錐体杆体ジストロフィー市場：概要
- 世界の錐体杆体ジストロフィーの市場規模
- 世界の錐体杆体ジストロフィー市場：タイプ別（X連鎖性錐体杆体ジストロフィー、常染色体優性錐体杆体ジストロフィー、常染色体劣性錐体杆体ジストロフィー）
- 世界の錐体杆体ジストロフィー市場：治療タイプ別（遺伝子治療、幹細胞治療、網膜インプラント手術、その他）
- 世界の錐体杆体ジストロフィー市場：エンドユーザー別（病院、専門クリニック、その他）
- 世界の錐体杆体ジストロフィー市場：地域別（北米、欧州、アジア太平洋、中東・アフリカ、ラテンアメリカ）
- 世界の錐体杆体ジストロフィー市場：タイプの分析
- 世界の錐体杆体ジストロフィー市場：タイプ別、概要
- 世界のX連鎖性錐体杆体ジストロフィーの市場規模
- 世界の常染色体優性錐体杆体ジストロフィーの市場規模
- 世界の常染色体劣性錐体杆体ジストロフィーの市場規模
- 世界の錐体杆体ジストロフィー市場：治療タイプの分析
- 世界の錐体杆体ジストロフィー市場：治療タイプ別、概要
- 世界の錐体杆体ジストロフィー遺伝子治療の市場規模
- 世界の錐体杆体ジストロフィー幹細胞治療の市場規模
- 世界の錐体杆体ジストロフィー網膜インプラント手術の市場規模
- 世界のその他の錐体杆体ジストロフィーの市場規模
- 世界の錐体杆体ジストロフィー市場：エンドユーザーの分析
- 世界の錐体杆体ジストロフィー市場：エンドユーザー別、概要
- 世界の病院における錐体杆体ジストロフィーの市場規模
- 世界の専門クリニックにおける錐体杆体ジストロフィーの市場規模
- 世界のその他の錐体杆体ジストロフィーの市場規模
第4章 地域市場の分析
- 北米の錐体杆体ジストロフィー市場：分析
- 北米の錐体杆体ジストロフィー市場：概要
- 北米の錐体杆体ジストロフィーの市場規模
- 北米の錐体杆体ジストロフィー市場：地域別（米国、カナダ、メキシコ）
- 米国の錐体杆体ジストロフィーの市場規模
- カナダの錐体杆体ジストロフィーの市場規模
- メキシコの錐体杆体ジストロフィーの市場規模
- 欧州の錐体杆体ジストロフィー市場：分析
- 欧州の錐体杆体ジストロフィー市場：概要
- 欧州の錐体杆体ジストロフィーの市場規模
- 欧州の錐体杆体ジストロフィー市場：地域別（ドイツ、英国、フランス、イタリア、その他の欧州）
- ドイツの錐体杆体ジストロフィーの市場規模
- 英国の錐体杆体ジストロフィーの市場規模
- フランスの錐体杆体ジストロフィーの市場規模
- イタリアの錐体杆体ジストロフィーの市場規模
- その他の欧州の錐体杆体ジストロフィーの市場規模
- アジア太平洋の錐体杆体ジストロフィー市場：分析
- アジア太平洋の錐体杆体ジストロフィー市場：概要
- アジア太平洋の錐体杆体ジストロフィーの市場規模
- アジア太平洋の錐体杆体ジストロフィー市場：地域別（中国、インド、日本、韓国、その他のアジア太平洋）
- 中国の錐体杆体ジストロフィーの市場規模
- 日本の錐体杆体ジストロフィーの市場規模
- インドの錐体杆体ジストロフィーの市場規模
- 韓国の錐体杆体ジストロフィーの市場規模
- その他のアジア太平洋の錐体杆体ジストロフィーの市場規模
- 中東・アフリカの錐体杆体ジストロフィー市場：分析
- 中東・アフリカの錐体杆体ジストロフィー市場：概要
- 中東・アフリカの錐体杆体ジストロフィーの市場規模
- ラテンアメリカの錐体杆体ジストロフィー市場：分析
- ラテンアメリカの錐体杆体ジストロフィー市場：概要
- ラテンアメリカの錐体杆体ジストロフィーの市場規模
第5章 COVID-19の影響
- 世界の錐体杆体ジストロフィー市場に対するCOVID-19の影響
- 世界の錐体杆体ジストロフィー市場に対するCOVID-19後の影響
第6章 市場力学
- 成長促進要因
- 錐体杆体ジストロフィーの有病率の増加
- 研究開発活動の増加
- 希少遺伝性疾患の罹患率の増加
- 錐体杆体ジストロフィーに関する意識の高まり
- 医療費の増加
- 錐体杆体ジストロフィーの遺伝子治療
- 課題
- 限られた患者数
- 規制と安全に関する懸念
- 市場動向
- 臨床試験の急増
- 新治療法の開発
- 新技術が早期発見に役立つ
第7章 競合情勢
- 世界の錐体杆体ジストロフィー市場：近年の発展
- 世界の錐体杆体ジストロフィー市場の企業：現在の情勢
第8章 企業プロファイル
- SparingVision
- Beacon Therapeutics
- Nanoscope Therapeutics, Inc.
- MeiraGTx Limited
- Ascidian Therapeutics, Inc.
- jCyte, Inc.
- BlueRock Therapeutics LP
- Zhongmou Therapeutics
List of Figures
- Figure 1: Cone Rod Dystrophy Segmentation
- Figure 2: Global Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 3: Global Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 4: Global Cone Rod Dystrophy Market by Type; 2024 (Percentage, %)
- Figure 5: Global Cone Rod Dystrophy Market by Treatment Type; 2024 (Percentage, %)
- Figure 6: Global Cone Rod Dystrophy Market by End user; 2024 (Percentage, %)
- Figure 7: Global Cone Rod Dystrophy Market by Region; 2024 (Percentage, %)
- Figure 8: Global X-Linked Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 9: Global X-Linked Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 10: Global Autosomal Dominant Cone Rod Dystrophy Market by Type; 2023-2024 (US$ Million)
- Figure 11: Global Autosomal Dominant Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 12: Global Autosomal Recessive Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 13: Global Autosomal Recessive Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 14: Global Gene Therapy Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 15: Global Gene Therapy Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 16: Global Stem Cell Therapy Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 17: Global Stem Cell Therapy Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 18: Global Retinal Implant Surgery Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 19: Global Retinal Implant Surgery Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 20: Global Others Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 21: Global Others Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 22: Global Hospitals Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 23: Global Hospitals Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 24: Global Specialty Clinics Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 25: Global Specialty Clinics Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 26: Global Others Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 27: Global Others Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 28: North America Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 29: North America Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 30: North America Cone Rod Dystrophy Market by Region; 2024 (Percentage, %)
- Figure 31: The US Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 32: The US Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 33: Canada Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 34: Canada Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 35: Mexico Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 36: Mexico Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 37: Europe Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 38: Europe Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 39: Europe Cone Rod Dystrophy Market by Region; 2024 (Percentage, %)
- Figure 40: Germany Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 41: Germany Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 42: UK Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 43: UK Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 44: France Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 45: France Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 46: Italy Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 47: Italy Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 48: Rest of Europe Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 49: Rest of Europe Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 50: Asia Pacific Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 51: Asia Pacific Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 52: Asia Pacific Cone Rod Dystrophy Market by Region; 2024 (Percentage, %)
- Figure 53: China Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 54: China Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 55: Japan Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 56: Japan Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 57: India Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 58: India Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 59: South Korea Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 60: South Korea Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 61: Rest of Asia Pacific Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 62: Rest of Asia Pacific Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 63: Middle East & Africa Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 64: Middle East & Africa Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 65: Latin America Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
- Figure 66: Latin America Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
- Figure 67: Rising Healthcare Expenditure
Cone rod dystrophy is a term used to describe a group of genetic or inherited eye disorders that affect the cone cells of the retina. These cells line the back of the eye in the region known as the retina. Cone photoreceptor cells are present throughout the retina, but are concentrated in the central region (the macula). They are useful for central (reading) vision. Rod photoreceptor cells are present throughout the retina except for the very centre and they help with night vision. The global cone rod dystrophy market value stood at US$131.29 million in 2024, and is expected to reach US$177.59 million by 2030.
The global cone rod dystrophy market growth is driven by factors such as the rising awareness of genetic disorders and growing demand for effective treatments. Diabetes also have a major impact on the growth of the Cone rod dystrophy Market. As of recent estimates from the National Eye Institute, about 1 in 40,000 individuals are affected by cone-rod dystrophy in the US alone, highlighting the critical need for effective treatment options. Currently, there is no treatment to stop a person with Cone Rod Dystrophy (CRD) from losing their vision. The primary goal of treating CRD is to slow disease progression, preserve remaining vision, and improve the quality of life for affected individuals. Possible future treatments for CRD may include gene therapy, stem cell therapy, and retinal implants. Looking ahead, the cone rod dystrophy market is projected to expand significantly from 2025 to 2030, fueled by rise in the government awareness programs, growing number of clinical trials, advancements in gene therapy and retinal implants, and increasing focus on personalized medicine. The market is expected to grow at a CAGR of 5.33% over the projected period of 2025-2030.
Market Segmentation Analysis:
By Type: The report provides the bifurcation of the global cone rod dystrophy market into three segments on the basis of type, namely, X-Linked Cone Rod Dystrophy, Autosomal Dominant Cone Rod Dystrophy, and Autosomal Recessive Cone Rod Dystrophy. The X-Linked Cone Rod Dystrophy segment dominated the X-Linked Cone Rod Dystrophy market in 2024, owing to the ongoing research which is exploring various potential therapeutic avenues, including gene therapies, pharmacological interventions targeting specific biochemical pathways involved in CRD pathogenesis, and neuroprotective agents aimed at preserving retinal function.
By Treatment Type: The report provides the bifurcation of the global cone rod dystrophy market into four segments on the basis of treatment type: Gene Therapy, Stem Cell Therapy, Retinal Implant Surgery, and Others. Gene therapy segment held the highest share in the market and and is expected to be the fastest-growing segment in the forecasted period. Currently there is no cure for Cone Rod Dystrophy, ongoing research into gene therapies holds promise for improving outcomes and potentially halting or slowing disease progression in the future. It refers to the transfer of functional genetic material into the affected cells to correct or replace the faulty genes, thereby potentially reversing the disease's progression, is expected to drive the cone rod dystrophy market during the forecast period. For instance, trials focused on adeno-associated virus (AAV) vectors show promise in delivering corrective genes to retinal cells. Several clinical trials are underway to evaluate the safety and efficacy of gene therapy for CRD.
By End User: The global cone rod dystrophy market can be divided into three segments, on the basis of end user, namely, drug Hospitals, Specialty Clinics, and Others. Hospitals segment held the highest share in the market, due to their comprehensive patient care services and advanced treatment options. The expansion of hospital infrastructure, particularly in emerging markets are driving growth. Future trends in hospitals involve the integration of advanced technologies, such as artificial intelligence and precision medicine, to enhance the delivery of several therapies for the treatment of CRD. The trend toward personalized medicine is expected to drive the growth. Moreover, the increasing collaboration between hospitals and biotechnology companies to conduct clinical trials and develop new therapies is likely to accelerate innovation and the adoption of several therapies to treat CRD in clinical practice.
By Region: The report provides insight into the global cone rod dystrophy market based on regions namely, North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America is the largest region of global cone rod dystrophy market, owing to rising cases of eye disorders. Also, increasing number of ophthalmic clinics has also led to market growth. The growing awareness and acceptance of early detection among patients and healthcare providers have also contributed to market expansion. Moreover, technological advancements in gene therapy and stem cell research, have opened new avenues for therapy development. Additionally, increased funding from both public and private sectors for research and clinical trials further supports the market's growth. The U.S. Food and Drug Administration (FDA) plays a crucial role in regulating and approving therapies, ensuring their safety and efficacy.
Asia Pacific is the fastest growing region of global cone rod dystrophy market, driven by a combination of increasing healthcare needs, significant investments in biotechnology, and supportive government policies. As a diverse and populous region, Asia Pacific offers immense potential for growth in therapies, particularly as countries within the region continue to advance their healthcare infrastructures and research capabilities. China is the largest region of Asia Pacific cone rod dystrophy market owing to significant investments in healthcare infrastructure and research. Japan is also a key player, with a significant market share. India is another significant market, with growing investments in healthcare and research contributing to the overall growth of the Cone Rod Dystrophy market in the region.
Market Dynamics:
Growth Drivers: The global cone rod dystrophy market has been rapidly growing over the past few years, due to factors such as increasing prevalence of cone rod dystrophy, rise in research and development activities, growing incidence of rare genetic disorders, rising awareness about cone rod dystrophy, rising healthcare expenditure, gene therapy for cone rod dystrophy, and many other factors. In the last few years, there has been a significant rise in instances of cone rod dystrophy, a condition that impacts about 2 million people globally. This ailment is a leading factor in causing vision loss among adults of working age. The rise in cone rod dystrophy cases globally is mainly due to two reasons: more people getting older and an increase in genetic disorders. The increasing prevalence of cone rod dystrophy is leading to a growing demand for the development of tailored therapies and interventions to address this condition.
Challenges: However, the global cone rod dystrophy market growth would be negatively impacted by various challenges such as, limited patient pool, and regulatory and safety considerations. The limited patient pool poses a significant challenge to the antiplatelet market. The rarity of the condition results in a limited patient pool, making it challenging for pharmaceutical companies to justify the high costs associated with research and development. Insurance coverage for these innovative treatments remains inconsistent, with many patients facing out-of-pocket expenses that can be prohibitive. This financial barrier can lead to disparities in access to care, particularly among low-income populations.
Trends: The global cone rod dystrophy market is projected to grow at a fast pace during the forecasted period, due to surge in clinical trials, development of novel therapies, newer techniques help in early detection, etc. The recent surge in clinical trials focusing on gene therapy for inherited retinal diseases underscores a pivotal shift towards more targeted therapies. The FDA has also reported a notable increase in the number of approved treatments for rare ocular disorders in the last decade, reflecting the growing commitment to addressing these unmet medical needs. Furthermore, the adoption of technologies like gene therapy has opened new avenues for treatment, potentially revolutionizing the management of cone-rod dystrophy. Moreover, collaboration between academic institutions, biotechnology firms, and patient advocacy groups can foster innovation and accelerate the development of new therapies. Partnerships aimed at raising awareness about the condition can also enhance patient recruitment for clinical trials, ultimately benefiting both patients and developers.
Impact Analysis of COVID-19 and Way Forward:
The COVID-19 pandemic initially disrupted the global cone rod dystrophy market by delaying clinical trials and research activities, but it also highlighted the potential of gene and stem cell therapies to develop treatment for cone rod dystrophy, leading to renewed interest and investment in the field. Post-COVID, the market is poised for significant growth as accelerated regulatory approvals and advancements in genetic and stem cell research are driving innovation and commercialization of new therapies.
Competitive Landscape:
The global cone rod dystrophy market is quite concentrated as the market is characterized by the presence of numerous players, including biotechnology companies, pharmaceutical companies, research institutes, hospitals, and specialty clinics, all of which are involved in various aspects of the market such as research, development, production, and commercialization of gene and stem cell therapies to treat cone rod dystrophy. Mergers and acquisitions are common as companies look to enhance their market position. Roche and Novartis continue to spearhead research initiatives aimed at advancing gene therapy and enhancing patient outcomes. The key players of the market are:
SparingVision
Beacon Therapeutics
Nanoscope Therapeutics, Inc.
MeiraGTx Limited
Ascidian Therapeutics, Inc.
jCyte, Inc.
BlueRock Therapeutics LP.
Zhongmou Therapeutics
The ongoing clinical trials of novel advanced therapies with improved efficiency and cost-effectiveness is positively contributing to market expansion, and entry of new advanced drugs into the market. Some recent approvals are as follows:
SparingVision's product, SPVN06, is gene agnostic treatment and therefore potentially capable of addressing more than 80 known genetic mutations of Retinitis Pigmentosa (RP). SPVN06 expresses proprietary neurotrophic factor (Rod derived Cone Viability Factor, RdCVF) and one enzyme reducing oxidative stress (Rod derived Cone Viability Factor Long form, RdCVFL) and is delivered via a single subretinal injection. The Company intends to start its first-in-human trial shortly after receiving a Clinical Trial Authorisation (CTA) and Investigational New Drug (IND). The first clinical trial will be a Phase I/II study aimed at testing the safety, tolerability, preliminary efficacy and quality of life of SPVN06.
Table of Contents
1. Executive Summary
2. Introduction
- 2.1 Cone Rod Dystrophy: An Overview
- 2.1.1 Introduction to Cone Rod Dystrophy
- 2.2 Cone Rod Dystrophy Segmentation: An Overview
- 2.2.1 Cone Rod Dystrophy Segmentation
3. Global Market Analysis
- 3.1 Global Cone Rod Dystrophy Market: An Analysis
- 3.1.1 Global Cone Rod Dystrophy Market: An Overview
- 3.1.2 Global Cone Rod Dystrophy Market by Value
- 3.1.3 Global Cone Rod Dystrophy Market by Type (X-Linked Cone Rod Dystrophy, Autosomal Dominant Cone Rod Dystrophy, and Autosomal Recessive Cone Rod Dystrophy)
- 3.1.4 Global Cone Rod Dystrophy Market by Treatment Type (Gene Therapy, Stem Cell Therapy, Retinal Implant Surgery, and Others)
- 3.1.4 Global Cone Rod Dystrophy Market by End User (Hospitals, Specialty Clinics, and Others)
- 3.1.5 Global Cone Rod Dystrophy Market by Region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
- 3.2 Global Cone Rod Dystrophy Market: Type Analysis
- 3.2.1 Global Cone Rod Dystrophy Market by Type: An Overview
- 3.2.2 Global X-Linked Cone Rod Dystrophy Market by Value
- 3.2.3 Global Autosomal Dominant Cone Rod Dystrophy Market by Value
- 3.2.4 Global Autosomal Recessive Cone Rod Dystrophy Market by Value
- 3.3 Global Cone Rod Dystrophy Market: Power Source Analysis
- 3.3.1 Global Cone Rod Dystrophy Market by Treatment Type: An Overview
- 3.3.2 Global Gene Therapy Cone Rod Dystrophy Market by Value
- 3.3.3 Global Stem Cell Therapy Cone Rod Dystrophy Market by Value
- 3.3.4 Global Retinal Implant Surgery Cone Rod Dystrophy Market by Value
- 3.3.5 Global Others Cone Rod Dystrophy Market by Value
- 3.4 Global Cone Rod Dystrophy Market: End User Analysis
- 3.4.1 Global Cone Rod Dystrophy Market by End User: An Overview
- 3.4.2 Global Hospitals Cone Rod Dystrophy Market by Value
- 3.4.3 Global Specialty Clinics Cone Rod Dystrophy Market by Value
- 3.4.4 Global Others Cone Rod Dystrophy Market by Value
4. Regional Market Analysis
- 4.1 North America Cone Rod Dystrophy Market: An Analysis
- 4.1.1 North America Cone Rod Dystrophy Market: An Overview
- 4.1.2 North America Cone Rod Dystrophy Market by Value
- 4.1.3 North America Cone Rod Dystrophy Market by Region (The US, Canada and Mexico)
- 4.1.4 The US Cone Rod Dystrophy Market by Value
- 4.1.5 Canada Cone Rod Dystrophy Market by Value
- 4.1.6 Mexico Cone Rod Dystrophy Market by Value
- 4.2 Europe Cone Rod Dystrophy Market: An Analysis
- 4.2.1 Europe Cone Rod Dystrophy Market: An Overview
- 4.2.2 Europe Cone Rod Dystrophy Market by Value
- 4.2.3 Europe Cone Rod Dystrophy Market by Region (Germany, UK, France, Italy, and Rest of Europe)
- 4.2.4 Germany Cone Rod Dystrophy Market by Value
- 4.2.5 UK Cone Rod Dystrophy Market by Value
- 4.2.6 France Cone Rod Dystrophy Market by Value
- 4.2.7 Italy Cone Rod Dystrophy Market by Value
- 4.2.8 Rest of Europe Cone Rod Dystrophy Market by Value
- 4.3 Asia Pacific Cone Rod Dystrophy Market: An Analysis
- 4.3.1 Asia Pacific Cone Rod Dystrophy Market: An Overview
- 4.3.2 Asia Pacific Cone Rod Dystrophy Market by Value
- 4.3.3 Asia Pacific Cone Rod Dystrophy Market by Region (China, India, Japan, South Korea, and Rest of Asia Pacific)
- 4.3.4 China Cone Rod Dystrophy Market by Value
- 4.3.5 Japan Cone Rod Dystrophy Market by Value
- 4.3.6 India Cone Rod Dystrophy Market by Value
- 4.3.7 South Korea Cone Rod Dystrophy Market by Value
- 4.3.8 Rest of Asia Pacific Cone Rod Dystrophy Market by Value
- 4.4 Middle East & Africa Cone Rod Dystrophy Market: An Analysis
- 4.4.1 Middle East & Africa Cone Rod Dystrophy Market: An Overview
- 4.4.2 Middle East & Africa Cone Rod Dystrophy Market by Value
- 4.5 Latin America Cone Rod Dystrophy Market: An Analysis
- 4.5.1 Latin America Cone Rod Dystrophy Market: An Overview
- 4.5.2 Latin America Cone Rod Dystrophy Market by Value
5. Impact of COVID-19
- 5.1 Impact of COVID-19 on Global Cone Rod Dystrophy Market
- 5.2 Post COVID-19 Impact on Global Cone Rod Dystrophy Market
6. Market Dynamics
- 6.1 Growth Drivers
- 6.1.1 Increasing Prevalence of Cone Rod Dystrophy
- 6.1.2 Rise in Research and Development Activities
- 6.1.3 Growing Incidence of Rare Genetic Disorders
- 6.1.4 Rising Awareness about Cone Rod Dystrophy
- 6.1.5 Rising Healthcare Expenditure
- 6.1.6 Gene Therapy for Cone Rod Dystrophy
- 6.2 Challenges
- 6.2.1 Limited Patient Pool
- 6.2.2 Regulatory and Safety Considerations
- 6.3 Market Trends
- 6.3.1 Surge in Clinical Trials
- 6.3.2 Development of Novel Therapies
- 6.3.3 Newer Techniques Help in Early Detection
7. Competitive Landscape
- 7.1 Global Cone Rod Dystrophy Market: Recent Developments
- 7.2 Global Cone Rod Dystrophy Market Players: Current Landscape
8. Company Profiles
- 8.1 SparingVision
- 8.1.1 Business Overview
- 8.1.2 Business Strategies
- 8.2 Beacon Therapeutics
- 8.2.1 Business Overview
- 8.2.2 Business Strategies
- 8.3 Nanoscope Therapeutics, Inc.
- 8.3.1 Business Overview
- 8.3.2 Business Strategies
- 8.4 MeiraGTx Limited
- 8.4.1 Business Overview
- 8.4.2 Business Strategies
- 8.5 Ascidian Therapeutics, Inc.
- 8.5.1 Business Overview
- 8.5.2 Business Strategies
- 8.6 jCyte, Inc.
- 8.6.1 Business Overview
- 8.6.2 Business Strategies
- 8.7 BlueRock Therapeutics LP
- 8.7.1 Business Overview
- 8.7.2 Business Strategies
- 8.8 Zhongmou Therapeutics
- 8.8.1 Business Overview
- 8.8.2 Business Strategy
